CU
Curative Biotechnology, Inc.
CUBT · OTC
$1.00 +8.67% (+$0.08)
1M +0.00%
Market Cap $6.82M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$1.1
10.0% upside
Current Price
$1
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CUBT is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
-
N/A EV/EBITDA N/A
P/S N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
57 /100
Average ROA 94.24%
Asset turnover 0.00x
ROIC 24.46%
Debt
0 /100
High Int. coverage -1.28x
Current ratio 0.02x
Net debt/EBITDA N/A
Stability
37 /100
Moderate EPS volatility 45.58%
Profitable years 0
Beta 1.30x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CUBT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
I. Richard Garr
Employees
4
Headquarters
Palm Beach Gardens